FDA approves GSK and Theravance COPD drug

Share this article:

US regulators approved Anoro Ellipta, an inhaled lung drug treatment for use in COPD. The drug—developed in tandem by Glaxo and Theravance—carries a black box warning for an increased risk of asthma-related death. In September, an advisory panel endorsed the drug 11-2. Analysts forecast annual sales of Anoro Ellipta at $2.65 billion by 2018, according to Thomson Reuters.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.